Elutia Inc. (ELUT)vsEdwards Lifesciences Corp (EW)
ELUT
Elutia Inc.
$0.75
-1.15%
HEALTHCARE · Cap: $36.36M
EW
Edwards Lifesciences Corp
$100.82
+1.46%
HEALTHCARE · Cap: $52.90B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 53561% more annual revenue ($6.51B vs $12.14M). ELUT leads profitability with a 426.9% profit margin vs 15.4%. EW earns a higher WallStSmart Score of 53/100 (C-).
ELUT
Avoid35
out of 100
Grade: F
EW
Buy53
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-0.0%
Fair Value
$0.90
Current Price
$0.75
$0.15 premium
Margin of Safety
+68.5%
Fair Value
$251.45
Current Price
$100.82
$150.63 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 221 in profit
Keeps 427 of every $100 in revenue as profit
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Strong operational efficiency at 29.8%
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Revenue declined 11.6%
Negative free cash flow — burning cash
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 25.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : ELUT
The strongest argument for ELUT centers on Return on Equity, Profit Margin, Price/Book. Profitability is solid with margins at 426.9% and operating margin at -243.1%.
Bull Case : EW
The strongest argument for EW centers on Debt/Equity, Altman Z-Score, Market Cap. Profitability is solid with margins at 15.4% and operating margin at 29.8%. Revenue growth of 13.6% demonstrates continued momentum.
Bear Case : ELUT
The primary concerns for ELUT are EPS Growth, Market Cap, Revenue Growth.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 54.6x leaves little room for execution misses.
Key Dynamics to Monitor
ELUT profiles as a declining stock while EW is a mature play — different risk/reward profiles.
ELUT carries more volatility with a beta of 0.92 — expect wider price swings.
EW is growing revenue faster at 13.6% — sustainability is the question.
EW generates stronger free cash flow (585M), providing more financial flexibility.
Bottom Line
EW scores higher overall (53/100 vs 35/100), backed by strong 15.4% margins and 13.6% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Elutia Inc.
HEALTHCARE · MEDICAL DEVICES · USA
Elutia Inc., a commercial-stage company, engages in developing and commercializing drug-eluting biomatrix technology to enhance surgical outcomes. The company is headquartered in Silver Spring, Maryland.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?